ClinicalTrials.gg
TerminatedNCT00977171CFS201Updated Jun 9, 2014Results posted

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

A Phase 2 interventional study of Droxidopa in Chronic Fatigue Syndrome, Orthostatic Hypotension and Neurally Mediated Hypotension, sponsored by Chelsea Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Chelsea Therapeutics (part of H. Lundbeck A/S) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.

Enrollment
56th of 58
3 · median 50
Started
2010
with 1 other
Phase 2
12 of 86
4 open now
Registered
18th of 86
by date

Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 56th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2010, is one of 12 in phase 2, and was the 18th registered.

Fatigue Syndrome, Chronic

265 studies on the registry are indexed under Fatigue Syndrome, Chronic; 63 are open to participants now.

Browse Fatigue Syndrome, Chronic studies →

Open to participants now

21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Fatigue Syndrome, Chronic studies recruiting now, 19 (42%) set no upper age limit and 20 (44%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Fatigue Syndrome, Chronic with a site in United States, or all of them as a file.
02

Study summary

A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not precisely understood, a dysfunction of the autonomic nervous system is thought to play a role in this subset of patients. In several small studies, subjects within this subset have noted improvement in their chronic fatigue symptoms when treated for their neurally mediated hypotension. As droxidopa acts on the autonomic nervous system and has been shown to ameliorate symptoms of neurally mediated hypotension, it is hypothesized that droxidopa could aid in the treatment of chronic fatigue symptoms.

Neurally mediated hypotension has been associated with patients suffering from chronic fatigue syndrome. Droxidopa meanwhile has been approved in Japan for the treatment of the symptoms of neurogenic orthostatic hypotension. As such, it is hypothesized that regulating the autonomic nervous system in patients with Chronic fatigue syndrome may prove to be clinically beneficial.

Read the detailed description

This is a phase II, single-center, open-label study to evaluate the efficacy and safety of droxidopa in subjects with chronic fatigue syndrome. The study will enroll enough subjects to allow 10 to be placed in the 12 week open label treatment period.

The study will consist of an initial screening period (up to 7 days) to confirm eligibility followed by an up to 2 week dose titration period, a 12 week treatment period and a 30 day follow up period to account for any new or on-going AEs. During the screening visit the following assessments will be recorded:

  • Demography;
  • Medical history;
  • Physical examination;
  • ECG;
  • Vital signs (BP, HR, weight)
  • Stand Test (measurement of BP and heart rate in the supine position (head and torso elevated at approximately 30° from horizontal) 10, 5, immediately before and 1, 5 and 10 minutes after standing);
  • Tilt Table Test
  • Blood samples for hematology and biochemistry;
  • Urine sample for urinalysis
  • Pregnancy test for females of child bearing potential.
  • Concomitant medication review o Subjects taking ephedrine or midodrine will stop taking these drugs for at least 7 days before the baseline assessments.

Within 7 days of successful screening, the following baseline assessments will be recorded:

  • Inclusion/Exclusion review;
  • Standing test (measurement of BP and heart rate 10, 5, immediately before and 1, 5 and 10 minutes after standing);
  • Vital signs (BP, HR, and weight);
  • Urine/serum pregnancy test for WOCP;
  • Concomitant medications;
  • Adverse events
  • Multidimensional Fatigue Inventory (MFI);
  • Brief Pain Inventory (BPI);
  • Clinical Global Impression of Severity (CGI-S);
  • Hospital Anxiety and Depression Scale (HADS);
  • Patient Global Impression of Improvement (PGI-I).

Following successful completion of screening and baseline procedures, subjects will enter the dose titration period. Subjects will be titrated upwards by 100 mg TID, preferably on consecutive days but definitely within 14 days of entry, until one of the following 3 criteria for ceasing dose escalation is met:

  1. The subject has a sustained SBP of greater than 140 mmHg or DBP of greater than 90 mmHg after 1, 5 or 10 minutes of standing, OR a sustained SBP greater than 150 mmHg or DBP greater than 100 mmHg measured in the supine position (head and torso elevated at approximately 30° from horizontal).
  2. The subject is unable to tolerate side effects believed to be related to the study medication;
  3. The subject reaches the maximum dose of 600 mg TID droxidopa. If a subject meets criteria 1 they will proceed directly to the treatment period at the previous lower dose. Subjects meeting criteria 2 will also proceed directly to the treatment period at the previous lower dose. Subjects meeting criteria 3 will enter immediately into the treatment period at 600 mg TID.

Subjects that meet criteria 1 or 2 at the initial 100 mg TID dose will be considered baseline failures.

During treatment, the investigator can determine whether to modify the subject's dose. This determination will be based on the subject's tolerability of droxidopa.

Upon successful completion of the dose titration, subjects will begin a 12 week treatment period. Subjects will return to the clinic every 4 weeks (+/- 3 days) for efficacy, safety and compliance check. A follow-up call will occur 30 days after completion or removal of the trial to record any new or on-going AEs.

droxidopa

droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989.

Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active.

The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.

Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.

03

Conditions studied

  • Chronic Fatigue Syndrome
  • Orthostatic Hypotension
  • Neurally Mediated Hypotension
  • Neurogenic Orthostatic Hypotension

Keywords

  • chronic fatigue syndrome
  • CFS
  • neurally mediated hypotension
  • NMH
  • neurogenic orthostatic hypotension
  • NOH
  • orthostatic hypotension
  • droxidopa
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

SUBJECT SELECTION CRITERIA:

  • Female and male outpatients between 18-65 years of age;
  • Subjects must be diagnosed with chronic fatigue syndrome (Per Fukuda Criteria);
  • Subjects must have neurally mediated hypotension (NMH) or neurogenic orthostatic hypotension (NOH) (confirmed via Tilt table test);
  • Voluntarily read and sign an .

MAIN SUBJECT EXCLUSION CRITERIA:

  • Taking a direct acting vasoconstricting agent (i.e. ephedrine or midodrine)

    • Patients taking vasoconstrictor agents such as ephedrine, or midodrine must stop taking these drugs at least 2 days or 5 half-lives (whichever is longer) prior to their baseline visit (Visit 2);
  • Taking anti-hypertensive medication for the treatment of high blood pressure
  • Women of who are not using a medically accepted ;
  • Subject Restrictions: : Female subjects should be either (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) who are using or agree to use acceptable methods of contraception throughout the study period and for 4 weeks after the last dose of product. Acceptable contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. If hormonal contraceptives are used they should be taken according to the package insert. WOCP who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for 4 weeks after the last dose of investigational product.
  • For WOCP a urine pregnancy test must be conducted at screening, baseline and study termination; the results must be negative at screening and at baseline. Any positive result will be confirmed by serum beta HCG pregnancy test.
  • Sexually active males whose partner is a WOCP must agree to use condoms for the duration of the study and for 4 weeks after the last dose;
  • Women who are pregnant, breast feeding, or plan to become pregnant during the course of this study;
  • Have a history of closed angle glaucoma;
  • Have uncontrolled supine hypertension, defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg or use of ≥2 antihypertensive medications;
  • Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;
  • Current melancholic major depressive disorder, or a previous diagnosis of psychosis, eating disorder, or bipolar disorder.
  • History of substance abuse or dependence within the past two years, excluding nicotine and caffeine.
  • Have a history of more than moderate alcohol consumption; (drinking in moderation is defined as having no more than 1 drink per day for women and no more than 2 drinks per day for men. This definition is referring to the amount consumed on any single day and is not intended as an average over several days)
  • Known or suspected to the study medication or any of its ingredients;
  • Serious unstable medical illness, including cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other unstable medical or psychiatric conditions that in the opinion of the investigator would compromise participation or would likely lead to hospitalization during the duration of the study.
  • Subjects who have acute liver injury (such as hepatitis) or severe cirrhosis ( Class C).
  • Subjects who are judged before randomization to be at suicidal risk by the clinical investigator.
  • Have diabetes mellitus or insipidus;
  • Have a known or suspected current . Patients with a history of cancer must be symptom- and treatment-free for at least 5 years before randomization, with the exception of patients with non-melanoma, non-invasive skin cancers (such as basal cell carcinoma), who should not have had an intervention or recurrence within one year of starting the study;;
  • Have known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;
  • In the investigator's opinion, have abnormalities on clinical examination or laboratory testing;
  • Have a serum creatinine level >1.3 mg/ml
  • In the investigator's opinion, are unable to stand up without human or physical assistance;
  • Conditions that Exclude a Diagnosis of CFS
  • Any active medical condition that may explain the presence of chronic fatigue, such as untreated hypothyroidism, sleep apnea and narcolepsy, and iatrogenic conditions such as side effects of medication.
  • Persistence of unresolved or relapsing condition that could explain the presence of chronic fatigue, Examples of illnesses that can present such a picture include some types of malignancies and chronic cases of or C virus infection.
  • Any past or current diagnosis of a major depressive disorder with psychotic or melancholic features such as; bipolar affective disorders; schizophrenia of any subtype; delusional disorders of any subtype; dementias of any subtype; anorexia nervosa; or bulemia nervosa.
  • Alcohol or other substance abuse, occurring within 2 years of the onset of chronicfatigue and any time afterwards.
  • Severe obesity as defined by a [body mass index = weight in kilograms ÷ (height in meters)2] equal to or greater than 45. [Note: body mass index values vary considerably among different age groups and populations. No"normal" or "average" range of values can be suggested in a fashion that is meaningful. The BMI range of 45 or greater was selected because it clearly falls within the range of severe obesity.]
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Droxidopa

    Drug: Droxidopa

Interventions

  • Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period

    Also known as: L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, L-DOPS

06

What researchers measure

Primary outcomes

  1. Patient Global Impression of Improvement

    The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.

    Time frame: Baseline to end of 12 week treatment period

07

Results

Posted Jun 9, 2014

Participant flow

Participant flow — Overall Study
MilestoneDroxidopa
Started3
Completed3
Not completed0

Outcome measures

PrimaryPatient Global Impression of Improvement

The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation.

Time frame:
Baseline to end of 12 week treatment period
Reported as:
Mean · units on a scale
Patient Global Impression of Improvement
units on a scaleDroxidopa
Patient Global Impression of Improvement3 ± 2.64

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Droxidopa—0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventDroxidopa
NauseaGastrointestinal disorders2/3
Localised infectionInfections and infestations1/3
Heart rate increasedInvestigations1/3
DiarrhoeaGastrointestinal disorders1/3
FibromyalgiaMusculoskeletal and connective tissue disorders1/3
Abdominal pain upperGastrointestinal disorders1/3

Baseline characteristics

3 patients enrolled in the study before it was stopped for difficulty recruiting subjects

Age, Continuous
Age, Continuous(years)Droxidopa
Mean51.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Droxidopa
Female3
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Droxidopa
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Droxidopa
United States3
08

Study locations

1 site
  • 7421 Carmel Executive Park Drive, Ste. 320
    Charlotte, North Carolina 28226, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2009
First posted
Sep 15, 2009
Start
Jul 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Jun 9, 2014
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00977171
Responsible party
Sponsor
First posted
Sep 15, 2009
Start date
Jul 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Jun 9, 2014
Last update
Jun 9, 2014

Study contacts

Charles W Lapp, M.D.
principal investigator · Hunter-Hopkins Center, P.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Droxidopa

Start the discussion